Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)

We report a case of refractory idiopathic childhood pyoderma gangrenosum in a young boy who had suffered from this disease since 3 years of age. He had unfavorable responses and intermittent relapses under different combinations of cytotoxic and steroid therapies. Although there was not much informa...

Descripción completa

Detalles Bibliográficos
Autores principales: Salehzadeh, Farhad, Mohammadikebar, Yusef, Enteshary, Afsaneh, Ghanbarpour, Omid, Mirzarahimi, Mehrdad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554516/
https://www.ncbi.nlm.nih.gov/pubmed/31239637
http://dx.doi.org/10.2147/BTT.S203753
_version_ 1783424980320518144
author Salehzadeh, Farhad
Mohammadikebar, Yusef
Enteshary, Afsaneh
Ghanbarpour, Omid
Mirzarahimi, Mehrdad
author_facet Salehzadeh, Farhad
Mohammadikebar, Yusef
Enteshary, Afsaneh
Ghanbarpour, Omid
Mirzarahimi, Mehrdad
author_sort Salehzadeh, Farhad
collection PubMed
description We report a case of refractory idiopathic childhood pyoderma gangrenosum in a young boy who had suffered from this disease since 3 years of age. He had unfavorable responses and intermittent relapses under different combinations of cytotoxic and steroid therapies. Although there was not much information available about infliximab use for biologic and childhood pyoderma gangrenosum, eventually we decided to use infliximab in this patient. Infliximab showed a dramatic response and resulted in full recovery during 2 years' follow-up.
format Online
Article
Text
id pubmed-6554516
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65545162019-06-25 Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG) Salehzadeh, Farhad Mohammadikebar, Yusef Enteshary, Afsaneh Ghanbarpour, Omid Mirzarahimi, Mehrdad Biologics Case Report We report a case of refractory idiopathic childhood pyoderma gangrenosum in a young boy who had suffered from this disease since 3 years of age. He had unfavorable responses and intermittent relapses under different combinations of cytotoxic and steroid therapies. Although there was not much information available about infliximab use for biologic and childhood pyoderma gangrenosum, eventually we decided to use infliximab in this patient. Infliximab showed a dramatic response and resulted in full recovery during 2 years' follow-up. Dove 2019-05-27 /pmc/articles/PMC6554516/ /pubmed/31239637 http://dx.doi.org/10.2147/BTT.S203753 Text en © 2019 Salehzadeh et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Salehzadeh, Farhad
Mohammadikebar, Yusef
Enteshary, Afsaneh
Ghanbarpour, Omid
Mirzarahimi, Mehrdad
Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)
title Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)
title_full Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)
title_fullStr Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)
title_full_unstemmed Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)
title_short Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)
title_sort infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (pg)
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554516/
https://www.ncbi.nlm.nih.gov/pubmed/31239637
http://dx.doi.org/10.2147/BTT.S203753
work_keys_str_mv AT salehzadehfarhad infliximabintreatmentofidiopathicrefractorychildhoodpyodermagangrenosumpg
AT mohammadikebaryusef infliximabintreatmentofidiopathicrefractorychildhoodpyodermagangrenosumpg
AT entesharyafsaneh infliximabintreatmentofidiopathicrefractorychildhoodpyodermagangrenosumpg
AT ghanbarpouromid infliximabintreatmentofidiopathicrefractorychildhoodpyodermagangrenosumpg
AT mirzarahimimehrdad infliximabintreatmentofidiopathicrefractorychildhoodpyodermagangrenosumpg

Ejemplares similares